BRPI0519656A2 - terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida - Google Patents

terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida

Info

Publication number
BRPI0519656A2
BRPI0519656A2 BRPI0519656-6A BRPI0519656A BRPI0519656A2 BR PI0519656 A2 BRPI0519656 A2 BR PI0519656A2 BR PI0519656 A BRPI0519656 A BR PI0519656A BR PI0519656 A2 BRPI0519656 A2 BR PI0519656A2
Authority
BR
Brazil
Prior art keywords
telmisartan
hydrochlorothiazide
combination therapy
angiotensin
treatment
Prior art date
Application number
BRPI0519656-6A
Other languages
English (en)
Inventor
Helmut E Schumacher
Peter Boehm
Axel Riedel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35589356&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0519656(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of BRPI0519656A2 publication Critical patent/BRPI0519656A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicinal Preparation (AREA)

Abstract

TERAPIA DE COMBINAÇçO COMPREENDENDO TELMISARTAN E HIDROCLOROTIAZIDA. A presente invenção refere-se a uma composição farmacêutica que compreende cerca de 80 mg de telmisartan e cerca de 25 mg de hidroclorotiazida ou cerca de 160 mg de telmisartan e cerca de 50 mg de hidroclorotiazida para o tratamento de hipertensão em pacientes com uma redução insuficiente na pressão sangúínea quando do tratamento com um antagonista do receptor da angiotensina II, ou uma composição farmacêutica de um antagonista do receptor da angiotensina II e uma dose baixa de hidroclorotiazida.
BRPI0519656-6A 2004-12-17 2005-12-09 terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida BRPI0519656A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63706204P 2004-12-17 2004-12-17
PCT/EP2005/013224 WO2006063737A1 (en) 2004-12-17 2005-12-09 Combination therapy comprising telmisartan and hydrochlorothiazide

Publications (1)

Publication Number Publication Date
BRPI0519656A2 true BRPI0519656A2 (pt) 2009-03-03

Family

ID=35589356

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0519656-6A BRPI0519656A2 (pt) 2004-12-17 2005-12-09 terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida

Country Status (15)

Country Link
EP (1) EP1827424A1 (pt)
JP (1) JP2008524136A (pt)
KR (1) KR20070097511A (pt)
CN (1) CN101080225A (pt)
AR (1) AR052052A1 (pt)
AU (1) AU2005315855A1 (pt)
BR (1) BRPI0519656A2 (pt)
CA (1) CA2589493A1 (pt)
EA (1) EA200701159A1 (pt)
IL (1) IL183944A0 (pt)
NO (1) NO20072325L (pt)
PE (1) PE20060768A1 (pt)
TW (1) TW200637546A (pt)
UY (1) UY29274A1 (pt)
WO (1) WO2006063737A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
US8637078B2 (en) * 2005-11-24 2014-01-28 Boehringer Ingelheim International Gmbh Bilayer tablet comprising telmisartan and diuretic
EP1970053A1 (en) * 2007-03-14 2008-09-17 Boehringer Ingelheim Pharma GmbH & Co. KG Pharmaceutical composition
CN101854920B (zh) * 2007-10-19 2013-05-01 大塚制药株式会社 基质型药物固体制剂
EP2203158A4 (en) 2007-10-30 2012-12-26 Reddys Lab Ltd Dr PHARMACEUTICAL FORMULATIONS WITH TELMISARTAN AND HYDROCHLORTHIAZIDE
ES2623329T3 (es) 2008-03-19 2017-07-11 Ratiopharm Gmbh Composición farmacéutica sólida que comprende un antagonista no peptídico de receptor de la angiotensina II y un diurético
JP5635491B2 (ja) * 2008-07-31 2014-12-03 武田薬品工業株式会社 固形医薬組成物
GB0822170D0 (en) * 2008-12-04 2009-01-14 Arrow Int Ltd Telmisartan with diuretic formulations
EP2443094B1 (en) 2009-06-19 2013-03-20 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of telmisartan
EP2448576A2 (en) * 2009-07-02 2012-05-09 Mahmut Bilgic Solubility enhancing pharmaceutical composition
WO2011002425A2 (en) * 2009-07-02 2011-01-06 Bilgig Mahmut Pharmaceutical composition increasing solubility and stability
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
EP2952196A4 (en) * 2013-01-31 2016-08-03 Sawai Seiyaku Kk MULTILAYER TABLET WITH TELMISARTAN AND HYDROCHLOROTHIAZIDE
EP3025711B1 (en) * 2013-07-23 2020-11-18 Daiichi Sankyo Company, Limited Medicine for preventing or treating hypertension
CN106562973A (zh) * 2016-11-06 2017-04-19 成都先先先生物科技有限公司 一种抗高血压药物复方制剂
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
CN108653227A (zh) * 2018-08-09 2018-10-16 湖北舒邦药业有限公司 一种替米沙坦氢氯噻嗪片及其制备方法
EP4029867A1 (en) * 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
EP1467712B2 (en) * 2002-01-16 2011-08-31 Boehringer Ingelheim Pharma GmbH & Co. KG Method of producing a bilayer pharmaceutical tablet comprising telmisartan and hydrochlorothiazide

Also Published As

Publication number Publication date
UY29274A1 (es) 2006-07-31
AU2005315855A1 (en) 2006-06-22
CA2589493A1 (en) 2006-06-22
KR20070097511A (ko) 2007-10-04
AR052052A1 (es) 2007-02-28
TW200637546A (en) 2006-11-01
EP1827424A1 (en) 2007-09-05
PE20060768A1 (es) 2006-09-29
IL183944A0 (en) 2007-10-31
JP2008524136A (ja) 2008-07-10
EA200701159A1 (ru) 2007-12-28
NO20072325L (no) 2007-07-06
CN101080225A (zh) 2007-11-28
WO2006063737A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
BRPI0519656A2 (pt) terapia de combinaÇço compreendendo telmisartan e hidroclorotiazida
UA101309C2 (ru) Антагонисты активина-actrii и их применение для повышения уровня эритроцитов
TW200612987A (en) Combination treatment for non-hematologic malignancies
BRPI0622054B8 (pt) composto e composição farmacêutica
ECSP099501A (es) Formulaciones de dosis unitaria y métodos para el tratamiento de la trombosis con un inhibidor oral del factor xa
UY32177A (es) Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
AR068185A1 (es) Composiciones de tabletas de desintegracion oral de lamotrigina
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
AR089862A1 (es) USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
WO2008027912A3 (en) Prediction of an agent's or agents' activity across different cells and tissue types
EA201100814A1 (ru) Фармацевтические формы применения, содержащие нифедипин или низолдипин и антагонист ангиотензина-ii и/или диуретик
BR112013010829B8 (pt) Composição farmacêutica intravenosa para proporcionar alívio da dor e/ou da inflamação
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
BR112012016783A2 (pt) "usos do composto de naltrexona ou sal farmaceuticamente aceitável da mesma a bupropiona ou sal farmaceuticamente aceitável da mesma ou de composição dos mesmos e métodos para proporcionar terapia"
MX2009011900A (es) Curacion de herida diabetica.
BRPI0513168A (pt) memantina como tratamento adjunto para antipsicóticos atìpicos em pacientes com esquizofrenia
BRPI0510895A (pt) formulação farmacêutica de 10-propargila-10-deazaaminopterina para tratamento de linfoma de célula t
MX341660B (es) Agonista del receptor de ghrelina para el tratamiento de caquexia.
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
EA200800397A1 (ru) Композиции тизанидина и способы лечения с применением композиций
BRPI0410374A (pt) composição farmacêutica que compreende valsartano
BRPI0519036A2 (pt) mÉtodo para o tratamento de um paciente acometido por uma doenÇa neuro-degenerativa; composiÇço farmacÊutica para tratar uma doenÇa neuro-degenerativa; e uso de um agonista 5-ht6 ou de um agonista 5-ht6
BR0315374A (pt) Compostos orgânicos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]